Otros idiomas Biogen Inc. Sao Paulo

Acciones

BIIB34

BRBIIBBDR001

Diferido Sao Paulo Otros sitios de cotización 20:05:44 03/07/2024			Varia. Cinco días.	Varia. 1 de enero.
211,9 ^BRL	-1,43 %		-1,43 %	+3,25 %

02/07	Los mercados de renta variable de EE.UU. terminan al alza el martes tras los comentarios del presidente de la Fed, Powell	MT
02/07	Los mercados de renta variable suben mayoritariamente intradía tras los comentarios del presidente de la Fed, Powell	MT

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen	15:41
July 22, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against BIIB	11:46
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit	05:01
US Equities Markets End Higher Tuesday Following Fed Chair Powell's Comments	02/07
Equity Markets Mostly Rise Intraday After Fed Chair Powell's Comments	02/07
Eli Lilly Alzheimer's drug approved by US FDA	02/07
Biogen Inc. Sued for Securities Law Violations - Contact the Schall Law Firm to Discuss Your Legal Rights BIIB	02/07
Biogen Closes Human Immunology Biosciences Acquisition	02/07
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB	02/07
Biogen Completes Acquisition of Human Immunology Biosciences	02/07
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biogen Inc.(BIIB) Shareholders	01/07
Japan's Eisai developing dementia drug for US market, Nikkei reports	30/06
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)	29/06
BIIB LAWSUIT ALERT: The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline	28/06
Biogen, Eisai Launch Leqembi in China to Treat Alzheimer's Disease	28/06
Eisai and Biogen launch Alzheimer's drug Leqembi in China	28/06
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China	28/06
Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China	28/06
Immunome, Inc. Appoints Phil Tsai as Chief Technical Officer	27/06
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit	26/06

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Biogen Inc. Sao Paulo

Acciones

BIIB34

BRBIIBBDR001

Otros idiomas

Filtros